| Name | Title | Contact Details |
|---|
GSB, formerly known as Guilford Savings Bank, is a mutual financial institution based in Connecticut, established in 1875. With over 145 years of experience, GSB has expanded from a single branch to eight locations, managing nearly $1 billion in assets. The bank focuses on community-oriented banking, emphasizing personalized service and long-term relationships with clients. GSB offers a comprehensive range of personal and business banking solutions. Their services include digital banking for real-time account management, tailored business banking for small to medium enterprises, and personal banking options such as checking and savings accounts, loans, and mortgages. The bank also provides specialized tools like online account opening and financial education resources. As a mutual bank, GSB reinvests its profits into community development and employee benefits, reflecting its commitment to local businesses and the shoreline communities of Connecticut. The bank promotes a culture of integrity and collaboration, ensuring that clients have direct access to staff and customized financial strategies. GSB continues to invest in digital innovation while maintaining a strong local presence.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
At POCN, we seek to support the careers and clinical practices of NPs and PAs - Advanced Clinicians by partnering with life science companies who recognize their critical role on the front lines of healthcare. We are the largest network of Advanced Clinicians in the U.S. and strive to support and enable success for them at every turn. POCN provides Advanced Clinicians with an opportunity engine to grow their careers, earn valuable financial incentives, and increase their clinical knowledge and practice productivity. Recognizing the vital relationship between NPs, PAs, and the broader healthcare and life sciences industries, POCN specializes in developing peer–validated programs that include engaging live and virtual events, helpful patient education resources, incentivized market research programs, clinical reference and prescribing tools, promoted speaking opportunities, as well as CME and continuous learning modules on a variety of disease states and therapies.
LifeLine Financial captains fast-growing businesses nationwide in service, technology, retail, and trades. We offer exceptional bookkeeping and accounting services nationwide. Call us today and grab a LifeLine (603) 782-4663